Expert psychiatric nurse practitioners stress the importance of familiarity with product inserts for each long-acting injectable antipsychotic to effectively manage missed doses in schizophrenia treatment.

Erzofri offers a new once-monthly injectable option for treating schizophrenia and schizoaffective disorder, potentially improving medication adherence for some patients.

Approximately one in four patients without observable responses to commands demonstrated cognitive activity on fMRI or EEG, suggesting a higher prevalence of covert consciousness than previously recognized.

The case highlights the critical importance of vigilant patient monitoring and rapid response to complications during anesthesia administration, even in routine outpatient procedures.

The combination of ponatinib and blinatumomab demonstrated a 95% complete response rate and 91% 3-year overall survival rate in patients with Ph-positive ALL.

The I-SPY2 trial demonstrates that novel treatment approaches can yield high pathologic complete response rates in rare histologic subtypes of high-risk breast cancer, potentially improving outcomes for these challenging cases.